Sichuan Huiyu Pharmaceutical Co Ltd Total Liabilities
Sichuan Huiyu Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Sichuan Huiyu Pharmaceutical Co Ltd (688553) has total liabilities worth CN¥1.16 Billion CNY (≈ $169.05 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sichuan Huiyu Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
Total liabilities of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024. This chart illustrates how Sichuan Huiyu Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Sichuan Huiyu Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sichuan Huiyu Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
engcon AB Cl B
ST:ENGCON-B
|
Sweden | Skr653.00 Million |
|
ZYLOX-TONBRDG.MED.TECH.H1
F:818
|
Germany | €341.97 Million |
|
Wuxi Jinyang New Materials Co. Ltd. A
SHE:301210
|
China | CN¥1.31 Billion |
|
SEP Analytical (Shanghai) Co. Ltd.
SHE:301228
|
China | CN¥465.36 Million |
|
Pexip Holding ASA
OL:PEXIP
|
Norway | Nkr508.69 Million |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
Brazil | R$35.19 Billion |
|
Phreesia Inc
NYSE:PHR
|
USA | $103.14 Million |
|
Winall Hi tech Seed
SHE:300087
|
China | CN¥4.34 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Sichuan Huiyu Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Sichuan Huiyu Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Sichuan Huiyu Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Sichuan Huiyu Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sichuan Huiyu Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total liabilities of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.19 Billion ≈ $174.46 Million |
+30.84% |
| 2023-12-31 | CN¥911.22 Million ≈ $133.34 Million |
+63.17% |
| 2022-12-31 | CN¥558.44 Million ≈ $81.72 Million |
-2.20% |
| 2021-12-31 | CN¥571.01 Million ≈ $83.56 Million |
+23.79% |
| 2020-12-31 | CN¥461.26 Million ≈ $67.50 Million |
+2.20% |
| 2019-12-31 | CN¥451.33 Million ≈ $66.04 Million |
-7.89% |
| 2018-12-31 | CN¥490.02 Million ≈ $71.71 Million |
+16.14% |
| 2017-12-31 | CN¥421.94 Million ≈ $61.74 Million |
-- |
About Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more